Calico gains P7C3 neurodegeneration program
2M BioTech L.P. (Dallas, Texas) granted Calico LLC (South San Francisco, Calif.) exclusive, worldwide rights to develop and commercialize a portfolio of modulators of nicotinamide phosphoribosyl transferase ( NamPRT; NAMPT). The deal includes 2M's preclinical P7C3 program, which has been focused on neurodegenerative diseases including Parkinson's disease and amyotrophic lateral sclerosis (ALS). 2M said Calico, which is led by CEO Arthur Levinson and was launched last year by Google Inc. (NASDAQ:GOOG), is evaluating which indications it will pursue for Phase I testing.
2M will receive an undisclosed upfront payment and is eligible for undisclosed milestones and royalties. Calico also will fund research laboratories in the Dallas area and elsewhere to support the program. 2M has rights to the compounds from The University of Texas Southwestern Medical Center at Dallas under a 2010 deal (see SciBX: Science Business eXchange, July 29, 2010). ...